Linaclotide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Linaclotide" in English language version.

refsWebsite

Global rank English rank

17web.archive.org

1^st place

14nih.gov

4^th place

7doi.org

2^nd place

2clincalc.com

3,912^th place

2,496^th place

2semanticscholar.org

11^th place

8^th place

2fda.gov

447^th place

338^th place

1cenblog.org

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1europa.eu

68^th place

117^th place

1springer.com

274^th place

309^th place

1bloomberg.com

99^th place

77^th place

1ub.edu

4,184^th place

7,294^th place

1mit.edu

415^th place

327^th place

1xconomy.com

low place

6,978^th place

1musc.edu

low place

1fdanews.com

low place

1nytimes.com

7^th place

1fortune.com

433^rd place

284^th place

1allergan.com

low place

1shareholder.com

6,233^rd place

5,563^rd place

1biopharmadive.com

low place

allergan.com

"Press release: Allergan Acquires Rights To Ironwoods Constella (Linaclotide) From Almirall In More Than 40 Countr". Allergan. 27 October 2015. Archived from the original on 15 April 2018. Retrieved 15 April 2018.

biopharmadive.com

LaMotta L. "How DTC got things moving for Linzess". BioPharma Dive. Archived from the original on 15 April 2018. Retrieved 15 April 2018.

bloomberg.com

Nocera J (9 January 2018). "How Allergan Continues to Make Drug Prices Insane". Bloomberg News. Archived from the original on 15 April 2018. Retrieved 15 April 2018.

cenblog.org

Oh SA (17 August 2011). "Macrocycle Milestone for Ironwood Pharma". The Haystack. Archived from the original on 27 November 2018. Retrieved 11 February 2017 – via CENBlog.org.

clincalc.com

"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Linaclotide - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

doi.org

Yu SW, Rao SS (September 2014). "Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide". Therapeutic Advances in Gastroenterology. 7 (5): 193–205. doi:10.1177/1756283X14537882. PMC 4107700. PMID 25177366.
Corsetti M, Tack J (February 2013). "Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation". United European Gastroenterology Journal. 1 (1): 7–20. doi:10.1177/2050640612474446. PMC 4040778. PMID 24917937.
Love BL, Johnson A, Smith LS (July 2014). "Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome". American Journal of Health-System Pharmacy. 71 (13): 1081–1091. doi:10.2146/ajhp130575. PMID 24939497.
Yu SW, Rao SS (September 2014). "Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide". Therapeutic Advances in Gastroenterology. 7 (5): 193–205. doi:10.1177/1756283X14537882. PMC 4107700. PMID 25177366.
Braga Emidio N, Tran HN, Andersson A, Dawson PE, Albericio F, Vetter I, Muttenthaler M (June 2021). "Improving the Gastrointestinal Stability of Linaclotide". Journal of Medicinal Chemistry. 64 (12): 8384–8390. doi:10.1021/acs.jmedchem.1c00380. PMC 8237258. PMID 33979161.
Góngora-Benítez M, Tulla-Puche J, Paradís-Bas M, Werbitzky O, Giraud M, Albericio F (2011). "Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide" (PDF). Biopolymers. 96 (1): 69–80. doi:10.1002/bip.21480. PMID 20560145. S2CID 46150263. Archived from the original (PDF) on 11 February 2017. Retrieved 10 February 2017.
Hornby PJ (2015). "Drug discovery approaches to irritable bowel syndrome". Expert Opinion on Drug Discovery. 10 (8): 809–824. doi:10.1517/17460441.2015.1049528. PMID 26193876. S2CID 207494271.

europa.eu

ema.europa.eu

"Constella EPAR". European Medicines Agency. 24 May 2023. Archived from the original on 22 June 2021. Retrieved 12 June 2023.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

fda.gov

"FDA approves first treatment for pediatric functional constipation". U.S. Food and Drug Administration (FDA) (Press release). 12 June 2023. Retrieved 12 June 2023.

fdanews.com

"Microbia, Forest Laboratories Announce Linaclotide Collaboration". FDA News. 17 September 2007. Archived from the original on 20 August 2016. Retrieved 15 September 2010.

fortune.com

Jones S, Burdette K, Wieczner J (30 July 2015). "From Actavis to Allergan: One pharma company's wild dealmaking journey". Fortune. Archived from the original on 27 September 2020. Retrieved 15 April 2018.

medicines.org.uk

"UK label: Linaclotide Summary of Product Characteristics". Electronic Medicines Compendium. September 2017. Archived from the original on 15 April 2018. Retrieved 15 April 2018.

mit.edu

wi.mit.edu

Withers M (22 September 2004). "Druhunters". Paradigm Magazine, Whitehead Institute. Archived from the original on 28 August 2021. Retrieved 15 April 2018.

musc.edu

academicdepartments.musc.edu

"Director profile: Mark Currie, Ph.D." MUSC Foundation for Research Development. Archived from the original on 16 April 2018. Retrieved 15 April 2018.

nih.gov

pubmed.ncbi.nlm.nih.gov

Yu SW, Rao SS (September 2014). "Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide". Therapeutic Advances in Gastroenterology. 7 (5): 193–205. doi:10.1177/1756283X14537882. PMC 4107700. PMID 25177366.
Hussain ZH, Everhart K, Lacy BE (February 2015). "Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies". Gastroenterology & Hepatology. 11 (2): 104–114. PMC 4836568. PMID 27099579.
Corsetti M, Tack J (February 2013). "Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation". United European Gastroenterology Journal. 1 (1): 7–20. doi:10.1177/2050640612474446. PMC 4040778. PMID 24917937.
Love BL, Johnson A, Smith LS (July 2014). "Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome". American Journal of Health-System Pharmacy. 71 (13): 1081–1091. doi:10.2146/ajhp130575. PMID 24939497.
Yu SW, Rao SS (September 2014). "Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide". Therapeutic Advances in Gastroenterology. 7 (5): 193–205. doi:10.1177/1756283X14537882. PMC 4107700. PMID 25177366.
Braga Emidio N, Tran HN, Andersson A, Dawson PE, Albericio F, Vetter I, Muttenthaler M (June 2021). "Improving the Gastrointestinal Stability of Linaclotide". Journal of Medicinal Chemistry. 64 (12): 8384–8390. doi:10.1021/acs.jmedchem.1c00380. PMC 8237258. PMID 33979161.
Góngora-Benítez M, Tulla-Puche J, Paradís-Bas M, Werbitzky O, Giraud M, Albericio F (2011). "Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide" (PDF). Biopolymers. 96 (1): 69–80. doi:10.1002/bip.21480. PMID 20560145. S2CID 46150263. Archived from the original (PDF) on 11 February 2017. Retrieved 10 February 2017.
Hornby PJ (2015). "Drug discovery approaches to irritable bowel syndrome". Expert Opinion on Drug Discovery. 10 (8): 809–824. doi:10.1517/17460441.2015.1049528. PMID 26193876. S2CID 207494271.

ncbi.nlm.nih.gov

Yu SW, Rao SS (September 2014). "Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide". Therapeutic Advances in Gastroenterology. 7 (5): 193–205. doi:10.1177/1756283X14537882. PMC 4107700. PMID 25177366.
Hussain ZH, Everhart K, Lacy BE (February 2015). "Treatment of Chronic Constipation: Prescription Medications and Surgical Therapies". Gastroenterology & Hepatology. 11 (2): 104–114. PMC 4836568. PMID 27099579.
Corsetti M, Tack J (February 2013). "Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation". United European Gastroenterology Journal. 1 (1): 7–20. doi:10.1177/2050640612474446. PMC 4040778. PMID 24917937.
Yu SW, Rao SS (September 2014). "Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide". Therapeutic Advances in Gastroenterology. 7 (5): 193–205. doi:10.1177/1756283X14537882. PMC 4107700. PMID 25177366.
Braga Emidio N, Tran HN, Andersson A, Dawson PE, Albericio F, Vetter I, Muttenthaler M (June 2021). "Improving the Gastrointestinal Stability of Linaclotide". Journal of Medicinal Chemistry. 64 (12): 8384–8390. doi:10.1021/acs.jmedchem.1c00380. PMC 8237258. PMID 33979161.

dailymed.nlm.nih.gov

"Linzess- linaclotide capsule, gelatin coated". DailyMed. 31 August 2021. Archived from the original on 29 March 2021. Retrieved 12 June 2023.

nytimes.com

Pollack, Andrew (13 September 2010). "Drug for Irritable Bowel Achieves Goals in Trial". The New York Times. Archived from the original on 20 December 2011. Retrieved 14 September 2010.

semanticscholar.org

api.semanticscholar.org

Góngora-Benítez M, Tulla-Puche J, Paradís-Bas M, Werbitzky O, Giraud M, Albericio F (2011). "Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide" (PDF). Biopolymers. 96 (1): 69–80. doi:10.1002/bip.21480. PMID 20560145. S2CID 46150263. Archived from the original (PDF) on 11 February 2017. Retrieved 10 February 2017.
Hornby PJ (2015). "Drug discovery approaches to irritable bowel syndrome". Expert Opinion on Drug Discovery. 10 (8): 809–824. doi:10.1517/17460441.2015.1049528. PMID 26193876. S2CID 207494271.

shareholder.com

files.shareholder.com

"8-K" (PDF). Ironwood. 31 January 2017. Archived from the original (PDF) on 15 April 2018. Retrieved 15 April 2018.

springer.com

adisinsight.springer.com

"Linaclotide - Ironwood Pharmaceuticals". AdisInsight. Archived from the original on 7 October 2017. Retrieved 15 April 2018.

ub.edu

pcb.ub.edu

Góngora-Benítez M, Tulla-Puche J, Paradís-Bas M, Werbitzky O, Giraud M, Albericio F (2011). "Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide" (PDF). Biopolymers. 96 (1): 69–80. doi:10.1002/bip.21480. PMID 20560145. S2CID 46150263. Archived from the original (PDF) on 11 February 2017. Retrieved 10 February 2017.

web.archive.org

Oh SA (17 August 2011). "Macrocycle Milestone for Ironwood Pharma". The Haystack. Archived from the original on 27 November 2018. Retrieved 11 February 2017 – via CENBlog.org.
"UK label: Linaclotide Summary of Product Characteristics". Electronic Medicines Compendium. September 2017. Archived from the original on 15 April 2018. Retrieved 15 April 2018.
"Linzess- linaclotide capsule, gelatin coated". DailyMed. 31 August 2021. Archived from the original on 29 March 2021. Retrieved 12 June 2023.
"Constella EPAR". European Medicines Agency. 24 May 2023. Archived from the original on 22 June 2021. Retrieved 12 June 2023.
"Linaclotide - Ironwood Pharmaceuticals". AdisInsight. Archived from the original on 7 October 2017. Retrieved 15 April 2018.
Nocera J (9 January 2018). "How Allergan Continues to Make Drug Prices Insane". Bloomberg News. Archived from the original on 15 April 2018. Retrieved 15 April 2018.
"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
Góngora-Benítez M, Tulla-Puche J, Paradís-Bas M, Werbitzky O, Giraud M, Albericio F (2011). "Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide" (PDF). Biopolymers. 96 (1): 69–80. doi:10.1002/bip.21480. PMID 20560145. S2CID 46150263. Archived from the original (PDF) on 11 February 2017. Retrieved 10 February 2017.
Withers M (22 September 2004). "Druhunters". Paradigm Magazine, Whitehead Institute. Archived from the original on 28 August 2021. Retrieved 15 April 2018.
Timmerman L (23 February 2009). "Xconomy: Renewables Aren't Just for Biofuels: Microbia Makes Industrial Chemicals a Bit Greener". Xconomy. Archived from the original on 16 April 2018. Retrieved 15 April 2018.
"Director profile: Mark Currie, Ph.D." MUSC Foundation for Research Development. Archived from the original on 16 April 2018. Retrieved 15 April 2018.
"Microbia, Forest Laboratories Announce Linaclotide Collaboration". FDA News. 17 September 2007. Archived from the original on 20 August 2016. Retrieved 15 September 2010.
Pollack, Andrew (13 September 2010). "Drug for Irritable Bowel Achieves Goals in Trial". The New York Times. Archived from the original on 20 December 2011. Retrieved 14 September 2010.
Jones S, Burdette K, Wieczner J (30 July 2015). "From Actavis to Allergan: One pharma company's wild dealmaking journey". Fortune. Archived from the original on 27 September 2020. Retrieved 15 April 2018.
"Press release: Allergan Acquires Rights To Ironwoods Constella (Linaclotide) From Almirall In More Than 40 Countr". Allergan. 27 October 2015. Archived from the original on 15 April 2018. Retrieved 15 April 2018.
"8-K" (PDF). Ironwood. 31 January 2017. Archived from the original (PDF) on 15 April 2018. Retrieved 15 April 2018.
LaMotta L. "How DTC got things moving for Linzess". BioPharma Dive. Archived from the original on 15 April 2018. Retrieved 15 April 2018.

xconomy.com

Timmerman L (23 February 2009). "Xconomy: Renewables Aren't Just for Biofuels: Microbia Makes Industrial Chemicals a Bit Greener". Xconomy. Archived from the original on 16 April 2018. Retrieved 15 April 2018.